Formations et évènements

ESMO

L'IFCT à l'ESMO 2026 : 

Analysis of the phase 2 part of IFCT-2103 DIAL phase 2-3 randomized trial, comparing continuation pembrolizumab (± pemetrexed) up to 2 years versus observation (± pemetrexed), in patients with metastatic Non-Small Cell Lung Cancer (mNSCLC) with disease control (DC) at 6 months
Anne Claire Toffart (La Tronche, France)
Sunday, 25.10.2026
Rapid oral session: 09:14 - 09:19
Abstract

Encorafenib plus binimetinib in patients (pts) with BRAFV600E-mutant advanced non-small cell lung cancer: updated efficacy and safety results from the IFCT-1904 ENCO-BRAF phase 2 trial
Charles Ricordel (Rennes, France)
Monday, 26.10.2026 (12:00 - 12:45)
Poster

Quality assurance of delineation and dosimetry of the RTEP7-IFCT-1402 multicentre randomised phase II trial
Laura Haas (Rouen, France)
Monday, 26.10.2026 (12:00 - 12:45)
Poster

IFCT-2404 COMET: a phase III trial of tepotinib versus investigator's choice treatment in patients with pre-treated MET exon 14 skipping NSCLC
Alexis Cortot (Lille, France)
Monday, 26.10.2026 (12:00 - 12:45)
Poster (Trial in progress)